The EGFRvIII variant in glioblastoma multiforme
- PMID: 19324552
- DOI: 10.1016/j.jocn.2008.12.005
The EGFRvIII variant in glioblastoma multiforme
Abstract
Glioblastoma multiforme (GBM) is the most common brain tumour and has the worst prognosis. Epidermal growth factor receptor (EGFR) gene amplification, mutation and re-arrangement (all of which enhance tumour growth, survival, progression and resistance to therapy) are frequently observed in primary GBM. The most common EGFR variant in GBM, the EGFRvIII, is characterised by a deletion of 267 amino acids in the extracellular domain, leading to a receptor which is unable to bind ligand yet is constitutively active. Together with its impaired internalisation and degradation, the EGFRvIII enhances the tumourigenic potential of GBM by activating and sustaining mitogenic, anti-apoptotic and pro-invasive signalling pathways. This EGFRvIII-mediated enhanced tumourigenicity combined with the lack of EGFRvIII expression in normal tissue makes it an ideal candidate for targeted therapy. This review summarizes the current knowledge about the role of EGFRvIII in GBM and discusses therapeutic agents targeting EGFRvIII that are being evaluated as treatments for GBM.
Similar articles
-
Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells.Cancer Res. 2006 Jan 15;66(2):867-74. doi: 10.1158/0008-5472.CAN-05-2753. Cancer Res. 2006. PMID: 16424019
-
Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype.Clin Cancer Res. 2002 Sep;8(9):2894-901. Clin Cancer Res. 2002. PMID: 12231534
-
Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.Cancer Res. 2003 Oct 15;63(20):6962-70. Cancer Res. 2003. PMID: 14583498
-
EGF receptor inhibitors in the treatment of glioblastoma multiform: old clinical allies and newly emerging therapeutic concepts.Eur J Pharmacol. 2009 Dec 25;625(1-3):23-30. doi: 10.1016/j.ejphar.2009.10.010. Epub 2009 Oct 18. Eur J Pharmacol. 2009. PMID: 19836372 Review.
-
The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered.FEBS J. 2013 Nov;280(21):5350-70. doi: 10.1111/febs.12393. Epub 2013 Jul 8. FEBS J. 2013. PMID: 23777544 Review.
Cited by
-
Principles in the Management of Glioblastoma.Genes (Basel). 2024 Apr 17;15(4):501. doi: 10.3390/genes15040501. Genes (Basel). 2024. PMID: 38674436 Free PMC article. Review.
-
Plasma ctDNA liquid biopsy of IDH1, TERTp, and EGFRvIII mutations in glioma.Neurooncol Adv. 2024 Mar 4;6(1):vdae027. doi: 10.1093/noajnl/vdae027. eCollection 2024 Jan-Dec. Neurooncol Adv. 2024. PMID: 38572065 Free PMC article.
-
The Lipidomic Signature of Glioblastoma: A Promising Frontier in Cancer Research.Cancers (Basel). 2024 Mar 8;16(6):1089. doi: 10.3390/cancers16061089. Cancers (Basel). 2024. PMID: 38539424 Free PMC article. Review.
-
Glioblastoma Therapy: Past, Present and Future.Int J Mol Sci. 2024 Feb 21;25(5):2529. doi: 10.3390/ijms25052529. Int J Mol Sci. 2024. PMID: 38473776 Free PMC article. Review.
-
EGFR signaling and pharmacology in oncology revealed with innovative BRET-based biosensors.Commun Biol. 2024 Mar 1;7(1):250. doi: 10.1038/s42003-024-05965-5. Commun Biol. 2024. PMID: 38429428 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous